Cytokine X-anti target A fusion protein - Kanaph Therapeutics
Alternative Names: Cytokine X-Anti-Target ALatest Information Update: 29 Sep 2020
At a glance
- Originator Kanaph Therapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytokine replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours